InvestorsHub Logo
Followers 274
Posts 32768
Boards Moderated 0
Alias Born 11/14/2013

Re: hankmanhub post# 669922

Sunday, 02/04/2024 12:32:05 PM

Sunday, February 04, 2024 12:32:05 PM

Post# of 708784
You are right, the comparison isn’t fair. SeaGen’s tech is merely a chemo attached to an antibody seeking one, just one antigen to kill the targeted cell. It is safer than just giving someone chemo though, because it limits damage to healthy cells. Its weakness is that it easily allows tumor escape.

NWBO’s technology is massively broad spectrum and targeted to the patient’s tumor cell antigens. It targets a multitude of different antigens on a multitude of different types of tumor cells. Thus limiting tumor escape. It doesn’t carry a manmade chemo payload, because it uses DCVax-l directed t-cells to attack and kill the target.

I was previously asked to compare the two company’s technologies. I did.

The post you commented on was a follow up making some further timing observations.

BTW, prerevenue companies are bought out all the time. Some for very large amounts. The purchasing BP uses future revenue calculations to justify their acquisition price.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News